Latest & greatest articles for terazosin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on terazosin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on terazosin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for terazosin

1. Terazosin

Terazosin Top results for terazosin - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for terazosin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. WITHDRAWN: Terazosin for benign prostatic hyperplasia.

WITHDRAWN: Terazosin for benign prostatic hyperplasia. BACKGROUND: Lower urinary tract symptoms associated with benign prostatic obstruction (BPO) occur in up to 70% of men over the age of 60 years. To relieve these bothersome symptoms, treatment options include alpha-antagonists, also know as alpha-blockers. OBJECTIVES: We conducted a systematic review to evaluate the effectiveness and adverse effects of the alpha-blocker, terazosin, for treatment of urinary symptoms associated with BPO (...) . SEARCH STRATEGY: Trials were searched in computerized general and specialized databases (MEDLINE, Cochrane Library), by checking bibliographies, and by contacting manufacturers and researchers. SELECTION CRITERIA: Studies were included if they (1) were randomized trials of at least 1 month duration, and (2) included men with symptomatic BPO and compared terazosin with placebo or active controls. DATA COLLECTION AND ANALYSIS: Study, patient characteristics and outcomes data were extracted in duplicate

Cochrane2011

3. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review

Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W CRD summary The authors concluded that tamsulosin improved International Prostate Symptom Score in the short-term compared to terazosin. High-quality trials were needed to assess the efficacy of tamsulosin (...) in the long term. Some review limitations made the reliability of the pooled results uncertain, but the overall conclusion was suitably cautious and appears appropriate. Authors' objectives To assess the safety and efficacy of tamsulosin compared to terazosin in patients with benign prostate hyperplasia. Searching PUBMED, EMBASE, The Cochrane Library (2007 Issue 4), Chinese Biomedical Literature Database and CMKI were searched to 2007 for published papers; search terms were not reported. Reference lists

DARE.2009

4. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia Hillman A L, Schwartz J S, Willian M K, Peskin E, Roehrborn C G, Oesterling J E, Mason M F, Maurath C J, Deverka P A, Padley R J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Terazosin in the treatment of moderate to severe benign prostatic hyperplasia. Type of intervention Treatment; palliative care. Economic study type Cost-effectiveness analysis. Study population Patients 55

NHS Economic Evaluation Database.1996

5. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. 8684407 1996 08 22 1996 08 22 2013 11 21 0028-4793 335 8 1996 Aug 22 The New England journal of medicine N. Engl. J. Med. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. 533-9 Men with benign prostatic hyperplasia can (...) be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared. We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow

NEJM1996

6. Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia

Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral (...) ) treatment with finasteride, terazosin, and transurethral resection of the prostate for men (TURP). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical population of men aged 55-75 years with at least moderate symptoms of prostatism. Setting The practice setting was hospital. The economic study was carried out in the US. Dates to which data relate Effectiveness data were obtained between 1988-1994. Resource data were obtained between 1994-1995

NHS Economic Evaluation Database.1995